Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aytu BioPharma, Inc. - Common Stock
(NQ:
AYTU
)
2.290
-0.030 (-1.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aytu BioPharma, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Aytu BioPharma to Present at Upcoming October 2025 Conferences
October 10, 2025
Via
ACCESS Newswire
11 Company Presentations Today at The MicroCap Rodeo Conference
September 25, 2025
Via
ACCESS Newswire
Aytu BioPharma to Present at Upcoming September 2025 Conferences
September 24, 2025
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
September 23, 2025
Via
ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
September 16, 2025
Via
ACCESS Newswire
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
June 06, 2025
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
February 12, 2025
Via
ACCESS Newswire
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
June 25, 2025
Via
ACCESS Newswire
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
June 23, 2025
Via
ACCESS Newswire
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
June 09, 2025
Via
ACCESS Newswire
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
June 06, 2025
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
May 14, 2025
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
November 13, 2024
Via
ACCESSWIRE
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
September 26, 2024
Via
ACCESSWIRE
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
August 06, 2024
Via
ACCESSWIRE
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
May 07, 2025
Via
ACCESS Newswire
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 21, 2025
Via
ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
February 05, 2025
Via
ACCESS Newswire
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 06, 2025
Via
ACCESSWIRE
Aytu BioPharma Disclosure Notification
December 03, 2024
Via
ACCESSWIRE
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
June 18, 2024
Via
ACCESSWIRE
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
November 22, 2024
Via
ACCESSWIRE
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
November 06, 2024
Via
ACCESSWIRE
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
October 14, 2024
Via
ACCESSWIRE
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
October 01, 2024
Via
ACCESSWIRE
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
September 16, 2024
Via
ACCESSWIRE
Sidoti Events, LLC's Virtual August Micro-Cap Conference
August 13, 2024
Via
ACCESSWIRE
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
August 08, 2024
Via
ACCESSWIRE
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
May 29, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and...
Via
Newsfile
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 23, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today